Sierra Oncology, Inc. Common Stock
SRRA
SRRA was delisted on the 30th of June, 2022.
75 hedge funds and large institutions have $641M invested in Sierra Oncology, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 39 funds opening new positions, 18 increasing their positions, 13 reducing their positions, and 10 closing their positions.
537% more call options, than puts
Call options by funds: $4.1M | Put options by funds: $644K
290% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 10
140% more capital invested
Capital invested by funds: $267M → $641M (+$374M)
63% more funds holding
Funds holding: 46 → 75 (+29)
60% more funds holding in top 10
Funds holding in top 10: 5 → 8 (+3)
38% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
+$40.5M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$30.5M |
| 3 |
O
OrbiMed
New York
|
+$14M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$13.4M |
| 5 |
Goldman Sachs
New York
|
+$12.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FM
Frazier Management
Seattle,
Washington
|
-$34.7M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$13.2M |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
-$10.1M |
| 4 |
NLVP
New Leaf Venture Partners
New York
|
-$8.15M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$6.61M |
SRRA Hedge Fund Activity: Q1 2022 in Review
75 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Sierra Oncology, Inc. Common Stock (SRRA) for Q1 2022, worth a combined $641M — up 140% from $267M a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new SRRA positions and 10 closed out — a net gain of 29 holders — while 18 added to existing stakes and 13 trimmed.
The largest buyer was Vivo Capital, adding an estimated $40.5M. The largest seller was Frazier Management, cutting an estimated $34.7M.
- 75 institutional investors held Sierra Oncology, Inc. Common Stock (SRRA) as of Q1 2022, up from 46 in Q4 2021.
- Funds reported $641M of Sierra Oncology, Inc. Common Stock stock for Q1 2022, up 140% quarter-over-quarter.
- 39 funds opened new Sierra Oncology, Inc. Common Stock positions in Q1 2022 and 10 closed out, a net change of +29 holders.
- The largest Sierra Oncology, Inc. Common Stock buyer in Q1 2022 was Vivo Capital, an estimated $40.5M added.
- The largest Sierra Oncology, Inc. Common Stock seller in Q1 2022 was Frazier Management, an estimated $34.7M sold.
Based on aggregated 13F filings for Q1 2022.